Gene: FXN
UniProt: Q9Y3D9
Molecular Weight: ~14 kDa
Subcellular Localization: Mitochondrial matrix (inner mitochondrial membrane)
Protein Family: Frataxin family, mitochondrial iron-binding proteins
FXN (Frataxin) is a mitochondrial protein essential for iron-sulfur cluster biogenesis. It is primarily known for its role in Friedreich's ataxia, but also has implications in other neurodegenerative conditions.
Frataxin is a small, highly conserved mitochondrial protein composed of 210 amino acids. The protein adopts an α/β fold consisting of a five-stranded β-sheet flanked by α-helices, forming a compact globular structure. The C-terminal region contains the conserved iron-binding site, while the N-terminal region mediates protein-protein interactions. The protein exists as a monomer in solution but can form oligomers under certain conditions.
Key structural features:
Frataxin is primarily localized to the mitochondrial matrix and is essential for iron-sulfur cluster (ISC) biosynthesis, a fundamental pathway for cellular metabolism. In neurons, frataxin plays several critical roles:
Iron-sulfur cluster biogenesis: Frataxin serves as an iron chaperone, donating Fe²⁺ to the ISC assembly machinery (ISCU, NFS1, ISD11). ISCs are essential cofactors for complexes I, II, and III of the electron transport chain, as well as for aconitase and various other enzymes.
Iron homeostasis: Frataxin helps regulate mitochondrial iron levels, preventing both iron deficiency and iron overload that can lead to oxidative stress.
Mitochondrial respiration: By facilitating ISC assembly, frataxin directly supports oxidative phosphorylation and ATP production in neurons, which have high energy demands.
Antioxidant defense: Through its role in ISC-containing antioxidant enzymes and mitochondrial function, frataxin helps protect neurons from oxidative damage.
Calcium homeostasis: Frataxin interacts with mitochondrial calcium handling proteins, influencing calcium signaling important for synaptic function and neuronal survival.
Friedreich's ataxia is an autosomal recessive neurodegenerative disorder caused by GAA trinucleotide repeat expansions in the first intron of the FXN gene, leading to reduced frataxin expression. FRDA is the most common inherited ataxia, characterized by:
The pathogenic mechanism involves:
Reduced frataxin expression has been implicated in:
| Mechanism | Description |
|---|---|
| GAA repeat expansion | Forms DNA triple helix and R-loop, blocking transcription elongation |
| Epigenetic silencing | Heterochromatin formation at expanded allele |
| Reduced ISC biosynthesis | Impaired activity of Fe-S containing enzymes |
| Mitochondrial iron overload | Deregulated iron import leads to oxidative damage |
| Metabolic dysfunction | Reduced ATP, increased ROS, impaired calcium handling |
Pandolfo et al., Friedreich ataxia: the clinical spectrum (2008)
Bencokova et al., Molecular therapeutic targets in Friedreich's ataxia (2023)
Martelli et al., Frataxin and mitochondrial Fe-S cluster biogenesis (2012)
Lynch et al., Iron metabolism and mitochondrial dysfunction in Friedreich's ataxia (2020)
Stirzaker et al., Gene therapy for Friedreich ataxia: a review (2024)
Saha et al., Therapeutic strategies targeting frataxin (2023)
This page was created as part of the NeuroWiki protein page initiative for neurodegeneration research.
Frataxin deficiency leads to Friedreich's ataxia (FA), a hereditary neurodegenerative disorder characterized by progressive loss of coordination, cardiomyopathy, and diabetes. In the nervous system, frataxin loss results in:
Current therapeutic approaches targeting frataxin include: